Advanced Cell Technology

In 2014 Advanced Cell Technology changed its company name to Ocata Therapeutics. In 2016 Astellas Pharma completed a tender offer to purchase Ocata Therapeutics through its subsidiary, Laurel Acquisition Inc. and Ocata Therapeutics became a subsidiary of Astellas. In 2018 the company changed its name to Astellas Institute for Regenerative Medicine (AIRM).

Advanced Cell Technology pioneered the first clinical investigation using human embryonic stem cell derived Retinal Pigment Epithelium (RPE) to treat retinal diseases including Stargardts Macular Degeneration (SMD) and Geographic Atrophy (GA), secondary to Age-related Macular Degeneration (AMD). The cell line generated by the company is named MA09-hRPE.

Advanced Cell Technology pioneered the first clinical investigation using human embryonic stem cell derived Retinal Pigment Epithelium (RPE) to treat retinal diseases including Stargardts Macular Degeneration (SMD) and Geographic Atrophy (GA), secondary to Age-related Macular Degeneration (AMD). The cell line generated by the company is named MA09-hRPE. In Phase 1/2 clinical trials MA09-hRPE cells were administered in suspension form beginning in April 2011 and completed in 2017 in eye centers in the United States, United Kingdom and South Korea (Clinicaltrial.gov identifiers: UK-SMD: NCT01469832; US-SMD: NCT01345006; US-AMD: NCT01344993).

In 2014, Advanced Cell Technology changed its company name to Ocata Therapeutics. In 2016 Astellas Pharma completed a tender offer to purchase Ocata Therapeutics through its subsidiary, Laurel Acquisition Inc. and Ocata Therapeutics became a subsidiary of Astellas. In 2018 the company changed its name to Astellas Institute for Regenerative Medicine (AIRM).

Advanced Cell Technology pioneered the first clinical investigation using human embryonic stem cell derived Retinal Pigment Epithelium (RPE) to treat retinal diseases including Stargardts Macular Degeneration (SMD) and Geographic Atrophy (GA), secondary to Age-related Macular Degeneration (AMD). The cell line generated by the company is named MA09-hRPE. In Phase 1/2 clinical trials MA09-hRPE cells were administered in suspension form beginning in April 2011 and completed in 2017 in eye centers in the United States, United Kingdom and South KoreaSouth Korea (Clinicaltrial.gov identifiers: UK-SMD: NCT01469832; US-SMD: NCT01345006; US-AMD: NCT01344993).

Advanced Cell Technology pioneered the first clinical investigation using human embryonic stem cell derived Retinal Pigment Epithelium (RPE) to treat retinal diseases including Stargardts Macular Degeneration (SMD) and Geographic Atrophy (GA), secondary to Age-related Macular Degeneration (AMD). The cell line generated by the company is named MA09-hRPE. In Phase 1/2 clinical trials MA09-hRPE cells were administered in suspension form beginning in April 2011 and completed in 2017 in eye centers in the United States, United Kingdom and South Korea (Clinicaltrial.gov identifiers: UK-SMD: NCT01469832; US-SMD: NCT01345006; US-AMD: NCT01344993).

In 2014 Advanced Cell Technology changed its company name to Ocata Therapeutics. In 2016 Astellas Pharma completed a tender offer to purchase Ocata Therapeutics through its subsidiary, Laurel Acquisition Inc. and Ocata Therapeutics became a subsidiary of Astellas. In 2018 the company changed its name to Astellas Institute for Regenerative Medicine (AIRM).

In 2014 Advanced Cell Technology changed its company name to Ocata Therapeutics. In 2016 Astellas Pharma completed a tender offer to purchase Ocata Therapeutics through its subsidiary, Laurel Acquisition Inc. Ocata Therapeutics became a subsidiary of Astellas.